Latest 10-K annual reports

BioAge Labs, Inc. announced positive interim Phase 1 data for its lead program BGE-102, demonstrating significant hsCRP reduction, and confirmed sufficient capital to fund operations through 2029.

Energy Focus, Inc. reported a reduced net loss in 2025, driven by cost controls, but faces ongoing going concern doubts and seeks new capital while expanding into AI data center and energy storage markets.

Leatt Corporation reported a significant financial turnaround in 2025, achieving a net income of $3.26 million on a 41% increase in revenues, compared to a net loss in the prior year.

Hour Loop, an online retailer, reported a 159% increase in net income for 2025, reaching $1.7 million, driven by revenue growth and operational efficiencies despite tariff challenges.

Smithfield Foods, Inc. reported a significant increase in net income from continuing operations for fiscal year 2025, driven by higher sales prices and strategic initiatives, while also announcing a major acquisition and plant construction.

FiscalNote Holdings, Inc. reported a 21% drop in total revenues for 2025, alongside a significant net loss and goodwill impairment, raising concerns about its financial stability and ability to meet debt obligations.

Core & Main, a leading specialty distributor for infrastructure products, reported increased net sales, gross profit, and net income for fiscal year 2025, alongside an expanded share repurchase program.

COMPASS Pathways reports positive Phase 3 results for COMP360 psilocybin in TRD, initiates PTSD trial, and strengthens financial position with recent capital raises.

Achieve Life Sciences' 2025 annual report highlights significant operating losses, ongoing financing needs, and potential FDA approval delays for cytisinicline, despite positive clinical trial results and breakthrough therapy designation.

FTC Solar, Inc. reported a significant net loss of $79.6 million in 2025, despite a 110.5% revenue increase, and disclosed substantial doubt about its ability to continue as a going concern.

Charging Robotics Inc. reports significant losses for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern despite strategic acquisitions and initial product orders in the growing EV charging and micro-mobility markets.

Permianville Royalty Trust reports mixed 2025 results with increased distributable income despite declining oil sales and reserves, driven by natural gas strength and cost controls.

Infinite Eagle Acquisition Corp., a blank check company, filed its annual report detailing its successful $345 million IPO and private placement, and outlining its strategy to identify a business combination target.

Cardinal Infrastructure Group Inc. reported significant revenue and Adjusted EBITDA growth for fiscal year 2025, driven by organic expansion and strategic acquisitions, while also detailing its recent IPO and future growth plans.

Lument Finance Trust reported a net loss of $7.5 million for 2025, a significant decline from the prior year's profit, alongside reduced dividends and increased credit loss provisions.

Planet Labs PBC reported a 26% increase in revenue to $307.7 million for fiscal year 2026, driven by defense and intelligence contracts, despite recording a net loss of $246.9 million.

Bold Eagle Acquisition Corp., a SPAC, reported a net income of $9.76 million for 2025, driven by trust account interest, but faces substantial doubt about its ability to continue as a going concern with an October 2026 business combination deadline looming.

Lowe's reports a 3.1% net sales increase to $86.3 billion in fiscal 2025, driven by strategic acquisitions and a focus on Pro customers, despite a decline in customer transactions.

Aspen Aerogels, Inc. filed an amended annual report correcting an inventory balance error, while the underlying financials reveal a significant net loss and revenue decline for 2025.

Battalion Oil Corporation reports a net income of $11.9 million for 2025, driven by derivative gains and cost reductions, amidst strategic asset divestitures and acquisitions, while addressing significant debt and NYSE listing compliance.

Merrill Lynch Depositor, Inc. files its 2025 annual report for INDEXPLUS Trust Series 2003-1, emphasizing compliance and outlining risks associated with its structured product.

Sutro Biopharma reported a net loss of $191.1 million for 2025, driven by strategic restructuring and a refocused pipeline on novel ADC candidates STRO-004, STRO-006, and STRO-227.

Ares Capital Corporation files an amendment to its 2025 annual report to include the audited financial statements of its significant subsidiary, Ivy Hill Asset Management, L.P.

PPLUS Trust Series GSC-2 filed its annual 10-K report for the fiscal year ended December 31, 2025, confirming compliance with servicing standards and detailing risks associated with its trust certificates.

Veris Residential, L.P. filed an amended 2025 annual report to update corporate governance, executive compensation, and security ownership details.

NRx Pharmaceuticals reports significant progress in its neuroplasticity drug pipeline and the expansion of its interventional psychiatry subsidiary, HOPE Therapeutics, despite facing substantial financial losses and a going concern warning.

Surrozen, Inc. reported a significant increase in net losses for 2025, driven by non-cash charges and increased R&D, while advancing its Wnt-pathway ophthalmology pipeline and securing new financing.

SilverBox Corp V, a blank check company, reported a net loss of $7.7 million for 2025 as it continues its search for an initial business combination, with $276 million held in trust.

Aardvark Therapeutics has voluntarily halted enrollment and dosing in its pivotal Phase 3 HERO trial for ARD-101 and Phase 2 ARD-201 trials following reversible cardiac observations in a healthy volunteer study, leading to significant stock price decline.

Greenland Technologies Holding Corporation reported an 8% revenue increase in 2025, driven by transmission product sales, despite the suspension of its HEVI electric industrial vehicle operations due to tariff uncertainty.